African Swine Fever Vaccine Research Just Got More Specific. Here's What the VAX4ASF Consortium Found.

African swine fever remains one of the most economically devastating diseases in global pig production, and one of the most frustrating from a vaccine development standpoint. No widely available vaccine exists. The virus is immunologically complex. And the gap between laboratory findings and a deployable product has proven stubbornly wide.

New findings from the European VAX4ASF consortium, presented at the project's second General Assembly in Gödöllő, Hungary in May 2026, don't close that gap overnight. But they move the science forward in two areas that matter: understanding how the virus manipulates the host immune response, and identifying which antigens might be worth prioritizing in future vaccine design.

What Researchers Found on the Virus Side

The consortium identified a group of candidate viral genes linked to the modulation of type I interferon pathways, the arm of innate immunity that serves as the body's first line of antiviral defense. Laboratory studies indicate that some of these genes can influence immune signaling in ways connected to viral virulence.

This is meaningful because it gives researchers a more specific map of how African swine fever virus works around the host's defenses. Identifying the mechanisms a pathogen uses to suppress or redirect immune signaling is foundational work for designing attenuated or replication-limited vaccine candidates, the types of vaccines that must be carefully engineered to stimulate protection without causing disease or enabling the virus to retain its pathogenic toolkit.

What Researchers Found on the Host Side

In parallel, the consortium analyzed how pigs respond immunologically after vaccination and subsequent exposure to the virus. Scientists identified a range of viral antigens recognized by the immune system, including a subset specifically associated with animals that remained protected after challenge.

That last point is where the practical value lies. The immune response to African swine fever virus is broad and variable, and not all immune activity translates to protection. Being able to identify which antigens correlate with survival after exposure gives vaccine developers a more targeted list of candidates to prioritize, rather than working across the full antigenic landscape of a highly complex pathogen.

The consortium is clear that these findings underscore the complexity of the problem as much as they advance the solution. Variability in immune response is a recurring challenge in ASF vaccine development, and the data reinforces why this work requires sustained, multidisciplinary effort rather than a single breakthrough.

The Bigger Picture

VAX4ASF is not just a vaccine project. The consortium is also developing DIVA diagnostic tests, the kind that allow differentiation between infected and vaccinated animals, which will be essential for any future vaccine's regulatory pathway and field utility. Epidemiological strategies for ASF control are also part of the program, reflecting a recognition that a vaccine alone won't solve a disease with the geographic spread and wildlife reservoir complexity of ASF.

The project brings together partners from across Europe and Africa, coordinated by HIPRA, with the Hungarian University of Agriculture and Life Sciences hosting the most recent assembly. The multidisciplinary structure reflects what effective work on a pathogen like ASF requires: virology, immunology, diagnostics, epidemiology, and industry expertise operating in coordination rather than in silos.

For veterinary professionals working in swine medicine or advising pork producers, the timeline to a commercially available ASF vaccine remains uncertain. But the science being built by consortia like VAX4ASF is the foundation on which that vaccine will eventually stand. These findings are part of that foundation.

TAGS: African swine fever, ASF, swine, vaccine development, VAX4ASF, food animal, infectious disease, global animal health, research, Europe